Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash from Financing Activities (2019 - 2025)

Volitionrx (VNRX) has disclosed Cash from Financing Activities for 9 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 71.45% year-over-year to $1.6 million, compared with a TTM value of $13.2 million through Sep 2025, up 30.47%, and an annual FY2024 reading of $8.7 million, down 70.13% over the prior year.
  • Cash from Financing Activities was $1.6 million for Q3 2025 at Volitionrx, down from $5.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $20.2 million in Q1 2021 and bottomed at -$460198.0 in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $4.1 million, with a median of $2.1 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 13203.23% in 2022, while the deepest fall reached 191.81% in 2022.
  • Year by year, Cash from Financing Activities stood at $2.1 million in 2021, then tumbled by 55.85% to $925964.0 in 2022, then soared by 307.19% to $3.8 million in 2023, then tumbled by 39.27% to $2.3 million in 2024, then crashed by 30.13% to $1.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for VNRX at $1.6 million in Q3 2025, $5.7 million in Q2 2025, and $3.7 million in Q1 2025.